Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 9/20 | 0.80 |
| ▸ | MAPT | P10636 | 9/20 | 0.80 |
| ▸ | TP53 | P04637 | 9/20 | 0.77 |
| ▸ | POLB | P06746 | 4/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12287180 | 0.91 | RXFP1 (0.84) | RXFP1MAPTTP53POLBTDP1 | |
| SCHEMBL14707918 | 0.91 | RXFP1 (0.84) | RXFP1MAPTTP53POLBTDP1 | |
| SCHEMBL12286338 | 0.90 | RXFP1 (0.82) | RXFP1MAPTTP53POLBTDP1 | |
| SCHEMBL14707926 | 0.89 | RXFP1 (0.81) | RXFP1MAPTTP53POLBTDP1 | |
| SCHEMBL14707930 | 0.89 | RXFP1 (1.00) | RXFP1MAPTTP53POLBTDP1 | |
| SCHEMBL12286277 | 0.89 | RXFP1 (0.81) | RXFP1MAPTTP53POLBTDP1 | |
| SCHEMBL12286033 | 0.89 | RXFP1 (0.81) | RXFP1MAPTTP53POLBTDP1 | |
| SCHEMBL12286372 | 0.89 | RXFP1 (0.81) | RXFP1MAPTTP53POLBTDP1 | |
| SCHEMBL12286278 | 0.88 | RXFP1 (0.86) | RXFP1MAPTTP53POLBTDP1 | |
| SCHEMBL12286355 | 0.88 | RXFP1 (0.85) | RXFP1MAPTTP53POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927561-B2 | Pyrimidinedione anti-viral compounds | Kineta, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927561-B2 | Pyrimidinedione anti-viral compounds | Kineta, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130045229-A1 | Anti-Viral Compounds | Kineta, Inc. (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045229-A1 | Anti-Viral Compounds | Kineta, Inc. (US) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045229-A1 | Anti-Viral Compounds | MAVS, EIF2AK2, IRF3 | RXFP1 3056/4885MAPT 3520/4885TP53 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.